Lipoprotein (a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease

Atherosclerosis

Volumn 246, Issue , 2016, Pages 214-220

  Niccoli, Giampaolo ^a   Cin, Diana ^b   Scalone, Giancarla ^a,c   Panebianco, Mario ^a   Abbolito, Sofia ^b   Cosentino, Nicola ^a   Jacoangeli, Francesca ^b   Refaat, Hesham ^a,d   Gallo, Giovanna ^b   Salerno, Gerardo ^b   Volpe, Massimo ^b   Crea, Filippo ^a   De Biase, Luciano ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF BARCELONA   (Spain)

^d ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

Coronary artery disease; Lipoprotein(a); Optical coherence tomography; Plaque morphology

Indexed keywords

LIPOPROTEIN A; BIOLOGICAL MARKER;

ACUTE CORONARY SYNDROME; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY OBSTRUCTION; FEMALE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; ATHEROSCLEROTIC PLAQUE; BLOOD; CLINICAL TRIAL; CORONARY ANGIOGRAPHY; CORONARY BLOOD VESSEL; CORONARY STENOSIS; DIAGNOSTIC IMAGING; ITALY; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PHENOTYPE; PREDICTIVE VALUE; RISK FACTOR; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; UPREGULATION;

ACUTE CORONARY SYNDROME; AGED; BIOMARKERS; CORONARY ANGIOGRAPHY; CORONARY STENOSIS; CORONARY VESSELS; FEMALE; HUMANS; LINEAR MODELS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; ROME; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, OPTICAL COHERENCE; UP-REGULATION;

EID: 84955437967     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.01.020     Document Type: Article

References (45)

1. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006, 3:e442.
2. Van Lennep J.E., Westerveld H.T., van Lennep H.W., Zwinderman A.H., Erkelens D.W., van der Wall E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2408-2413.
3. Lamarche B., Moorjani S., Lupien P.J., Cantin B., Bernard P.M., Dagenais G.R., et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular Study. Circulation 1996, 94:273-278.
4. Lamarche B., Tchernof A., Mauriege P., Cantin B., Dagenais G.R., Lupien P.J., et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA 1998, 279:1955-1961.
5. Westerveld H.T., van Lennep J.E., van Lennep H.W., Liem A.H., de Boo J.A., van der Schouw Y.T., et al. Apolipoprotein B and coronary artery disease in women: a cross-sectional study in women undergoing their first coronary angiography. Arterioscler. Thromb. Vasc. Biol. 1998, 18:1101-1107.
6. Sharrett A.R., Ballantyne C.M., Coady S.A., Heiss G., Sorlie P.D., Catellier D., et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in communities (ARIC) study. Circulation 2001, 104:1108-1113. Atherosclerosis Risk in communities Study Group.
7. Walldius G., Jungner I., Holme I., Aastveit A.H., Kolar W., Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358:2026-2033.
8. Gotto A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., Weis S., et al. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas coronary atherosclerosis prevention study (AFCAPS/TexCAPS). Circulation 2000, 101:477-484.
9. Genest J., Jenner J.L., McNamara J.R., Ordovas J.M., Silberman S.R., Wilson P.W., et al. Prevalence of lipoprotein(a) [Lp(a)] excess in coronary artery disease. Am. J. Cardiol. 1991, 67:1039-1045.
10. Labeur C., De Bacquer D., De Backer G., Vincke J., Muyldermans L., Vandekerckhove Y., et al. Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin. Chem. 1992, 38:2261-2266.
11. McLean J.W., Tomlinson J.E., Kuang W.J. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1990, 330:132-137.
12. Scanu A.M. Lipoprotein(a). A potential bridge between the fields of atherosclerosis and thrombosis. Arch. Pathol. Lab. Med. 1988, 33:33-39.
13. Bogaty P., Brecker S.J., White S.E., Stevenson R.N., el-Tamimi H., Balcon R., et al. Comparison of coronary angiographic findings in acute and chronic 1st presentation of ischemic-heart-disease. Circulation 1993, 87:1938-1946.
14. Sullivan D.R., Marwick T.H., Freedman S.B. A new method of scoring coronary angiograms to reflect extent of coronary atherosclerosis and improve correlation with major risk factors. Am. Heart J. 1990, 119:1262-1279.
15. Prati F., Guagliumi G., Mintz G.S., Costa M., Regar E., Akasaka T., et al. Expert review document part 2: methodology, terminology and clinical applications of optical coherence tomography for the assessment of interventional procedures. Eur. Heart J. 2012, 33:2513-2520. Expert's OCT Review Document.
16. Prati F., Regar E., Mintz G.S., Arbustini E., Di Mario C., Jang I.K., et al. Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: Physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis. Eur. Heart J. 2010, 31:401-415.
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation, and treatment of high blood cholesterol in Adults (Adult treatment Panel III). Third report of the National cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment Panel III) final report. Circulation 2002, 106:3143-3421.
18. Niccoli G., Giubilato S., Di Vito L., Leo A., Cosentino N., Pitocco D., et al. Severity of coronary atherosclerosis in patients with a first acute coronary event: a diabetes paradox. Eur. Heart J. 2013, 34:729-741.
19. Bdeir K., Cane W., Canziani G., Chaiken I., Weisel J., Koschinsky M.L., et al. Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 1999, 94:2007-2019.
20. Nordestgaard B.G., Chapman M.J., Ray K., Borén J., Andreotti F., Watts G.F., et al. European atherosclerosis society consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur. Heart J. 2010, 31:2844-2853.
21. Grainger D.J., Kirschenlohr H.L., Metcalfe J.C., Weissberg P.L., Wade D.P., Lawn R.M. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science 1993, 260:1655-1658.
22. Imhof A., Rothenbacher D., Khuseyinova N., Hoffmeister A., Maerz W., Nauck M., et al. Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease. Eur. J. Cardiovasc Prev. Rehabil. 2003, 10:362-370.
23. Schwartzman R.A., Cox I.D., Poloniecki J., Crook R., Seymour C.A., Kaski J.C. Elevated plasma lipoprotein(a) is associated with coronary artery disease in patients with chronic stable angina pectoris. J. Am. Coll. Cardiol. 1998, 31:1260-1266.
24. Jiang Y., Guo K., Chen M., Bao J., Shen C., Li Y. Serum lipoprotein(a) positively correlates with coronary artery calcification in low-risk chinese han patients: a study from a single center. PLoS One 2013, 8:e71673.
25. Hikita H., Shigeta T., Kojima K., Oosaka Y., Hishikari K., Kawaguchi N., et al. Lipoprotein(a) is an important factor to determine coronary artery plaque morphology in patients with acute myocardial infarction. Coron. Artery Dis. 2013, 24:381-385.
26. Hartmann M., von Birgelen C., Mintz G.S., Stoel M.G., Eggebrecht H., Wieneke H., et al. Relation between lipoprotein(a) and fibrinogen and serial intravascular ultrasound plaque progression in left main coronary arteries. J. Am. Coll. Cardiol. 2006, 48:446-452.
27. Niccoli G., Biasucci L.M., Biscione C., Fusco B., Porto I., Leone A.M., et al. Independent prognostic value of C-reactive protein and coronary artery disease extent in patients affected by unstable angina. Atherosclerosis 2008, 196:779-785.
28. Jang I.K., Bouma B.E., Kang D.H., Park S.J., Park S.W., Seung K.B., et al. Visualization of coronary atherosclerotic plaques in patients using optical coherence tomography: comparison with intravascular ultrasound. J. Am. Coll. Cardiol. 2002, 39:604-609.
29. Niccoli G., Liuzzo G., Montone R.A., Crea F. Advances in mechanisms, imaging and management of the unstable plaque. Atherosclerosis 2014, 233:467-477.
30. Sotiriou S.N., Orlova V.V., Al-Fakhri N., Ihanus E., Economopoulou M., Isermann B., et al. Lipoprotein(a) in atherosclerotic plaques recruits inflammatory cells through interaction with Mac-1 integrin. FASEB J. 2006, 20:559-561.
31. Tsimikas S., Tsironis L.D., Tselepis A.D. New insights into the role of lipoprotein(a)-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2007, 27:2094-2099.
32. Dangas G., Mehran R., Harpel P.C., Sharma S.K., Marcovina S.M., Dube G., et al. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. J. Am. Coll. Cardiol. 1998, 32:2035-2042.
33. Hervio L., Chapman M.J., Thillet J., Loyau S., Angles-Cano E. Does apolipoprotein(a) heterogeneity influence lipoprotein(a) effects on fibrinolysis?. Blood 1993, 82:392-397.
34. Feric N.T., Boffa M.B., Johnston S.M., Koschinsky M.L. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation. J. Thromb. Haemost. 2008, 6:2113-2120.
35. Pan S., Kleppe L.S., Witt T.A., Mueske C.S., Simari R.D. The effect of vascular smooth muscle cell-targeted expression of tissue factor pathway inhibitor in a murine model of arterial thrombosis. Thromb. Haemost. 2004, 92:495-502.
36. Apolipoprotein Barre DE. (a) mediates the lipoprotein (a)-induced biphasic shift in human platelet cyclic AMP. Thromb. Res. 2003, 112:321-324.
37. Nestel P.J., Barnes E.H., Tonkin A.M., Simes J., Fournier M., White H.D., et al. Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2902-2908.
38. Kavousi M., Leening M.J., Nanchen D., Greenland P., Graham I.M., Steyerberg E.W., et al. Comparison of application of the ACC/AHA guidelines, adult treatment panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA 2014, 311:1416-1423.
39. D'Agostino R.B., Grundy S., Sullivan L.M., Wilson P. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. JAMA 2001, 286:180-187. CHD Risk Prediction Group.
40. Schaefer E.J., Lamon-Fava S., Jenner J.L., McNamara J.R., Ordovas J.M., Davis C.E., et al. Lipoprotein(a) levels and risk of coronary heart disease in men. The lipid research clinics coronary primary prevention trial. J. Am. Med. Assoc. 1994, 271:999-1003.
41. Bostom A.G., Gagnon D.R., Cupples L.A., Wilson P.W., Jenner J.L., Ordovas J.M., et al. A prospective investigation of elevated lipoprotein(a) detected by electrophoresis and cardiovascular disease in women. The framing-ham heart study. Circulation 1994, 90:1688-1695.
42. Willeit P., Kiechl S., Kronenberg F., Witztum J.L., Santer P., Mayr M., Xu Q., Mayr A., Willeit J., Tsimikas S. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. J. Am. Coll. Cardiol. 2014, 64:851-860.
43. Chapman M.J., Le Goff W., Guerin M., Kontush A. Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur. Heart J. 2010, 31:149-164.
44. Tsimikas S., Viney N.J., Hughes S.G., Singleton W., Graham M.J., Baker B.F., et al. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015, 22. http://dx.doi.org/10.1016/S0140-6736(15)61252-1.
45. Neeland I.J., Patel R.S., Eshtehardi P., Dhawan S., McDaniel M.C., Rab S.T., et al. Coronary angiographic scoring systems: an evaluation of their equivalence and validity. Am. Heart J. 2012, 164:547-552.